Literature DB >> 23761150

RECall for automated genotypic tropism testing.

Christian Pou1, Rocío Bellido, Maria Casadellà, Teresa Puig, Bonaventura Clotet, Richard Harrigan, Roger Paredes.   

Abstract

Standardization of sequence chromatogram analysis is required for consistent genotypic tropism determination across laboratories. A freely available, fast, and automated chromatogram analysis tool (RECall) provided tropism interpretations equivalent to those of manual sequence editing of 521 V3 loop HIV-1 population sequences, suggesting that RECall can be useful in standardizing genotypic tropism testing across laboratories.

Entities:  

Mesh：

Year:  2013        PMID： 23761150      PMCID： PMC3719662          DOI： 10.1128/JCM.00935-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  8 in total

1.  Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.

Authors:  Conan K Woods; Chanson J Brumme; Tommy F Liu; Celia K S Chui; Anna L Chu; Brian Wynhoven; Tom A Hall; Christina Trevino; Robert W Shafer; P Richard Harrigan
Journal:  J Clin Microbiol       Date:  2012-03-07       Impact factor: 5.948

2.  Bioinformatics prediction of HIV coreceptor usage.

Authors:  Thomas Lengauer; Oliver Sander; Saleta Sierra; Alexander Thielen; Rolf Kaiser
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

3.  Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.

Authors:  Rachel A McGovern; Alexander Thielen; Simon Portsmouth; Theresa Mo; Winnie Dong; Conan K Woods; Xiaoyin Zhong; Chanson J Brumme; Douglass Chapman; Marilyn Lewis; Ian James; Jayvant Heera; Hernan Valdez; P Richard Harrigan
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

Review 4.  Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.

Authors:  Eva Poveda; Roger Paredes; Santiago Moreno; José Alcamí; Juan Córdoba; Rafael Delgado; Félix Gutiérrez; Josep M Llibre; Miguel García Deltoro; José Hernández-Quero; Federico Pulido; José Antonio Iribarren; Federico García
Journal:  AIDS Rev       Date:  2012 Jul-Sep       Impact factor: 2.500

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

Review 6.  European guidelines on the clinical management of HIV-1 tropism testing.

Authors:  L P R Vandekerckhove; A M J Wensing; R Kaiser; F Brun-Vézinet; B Clotet; A De Luca; S Dressler; F Garcia; A M Geretti; T Klimkait; K Korn; B Masquelier; C F Perno; J M Schapiro; V Soriano; A Sönnerborg; A-M Vandamme; C Verhofstede; H Walter; M Zazzi; C A B Boucher
Journal:  Lancet Infect Dis       Date:  2011-03-21       Impact factor: 25.071

7.  Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.

Authors:  Anna Bonjoch; Christian Pou; Núria Pérez-Álvarez; Rocío Bellido; Maria Casadellà; Jordi Puig; Marc Noguera-Julian; Bonaventura Clotet; Eugènia Negredo; Roger Paredes
Journal:  J Antimicrob Chemother       Date:  2013-01-25       Impact factor: 5.790

8.  Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism.

Authors:  Stéphanie Raymond; Pierre Delobel; Maud Mavigner; Michelle Cazabat; Corinne Souyris; Karine Sandres-Sauné; Lise Cuzin; Bruno Marchou; Patrice Massip; Jacques Izopet
Journal:  AIDS       Date:  2008-09-12       Impact factor: 4.177
  8 in total
  1 in total

1.  HIV-1 tropism: a comparison between RNA and proviral DNA in routine clinical samples from Chilean patients.

Authors:  Pablo Ferrer; Luisa Montecinos; Mario Tello; Rocio Tordecilla; Consuelo Rodríguez; Marcela Ferrés; Carlos M Pérez; Carlos Beltrán; Maria A Guzmán; Alejandro Afani
Journal:  Virol J       Date:  2013-10-28       Impact factor: 4.099
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.